CombinatoRx makes further cuts following Phase II failure
This article was originally published in Scrip
Executive Summary
CombinatoRx is to reduce its workforce by a further 30 employees after its lead product Synavive (CRx-102) failed to reach its Phase II primary endpoint last month, sending its stock plummeting by 77%. The company has now reduced its workforce by around 65%, having initially announced a 45% reduction of its Cambridge, Massachusetts, workforce earlier this month. Around 55 employees will remain after the restructuring and will primarily be focused on research activities and partnering assets. CombinatoRx expects to incur restructuring charges of $3.2-4 million in the fourth quarter of this year, but expects its annual cash burn to fall by $5-10 million. The measures should allow it to operate without additional equity financing for at least four more years, CombinatoRx said. The company still believes that Synavive may have commercial potential and is currently engaged in partnership conversations.
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.